Correspondence 0001493152-24-036921 from bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc.
Date: Sept. 17, 2024 · CIK: 0001712762 · Accession: 0001493152-24-036921
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282045
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Jane Park bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed September 11, 2024 File No: 333-282045
Dear Ms. Park:
bioAffinity Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-282045), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Thursday, September 19, 2024, at 4:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request for acceleration has been granted.
Very truly yours,
BIOAFFINITY TECHNOGIES, INC.
Show Raw Text
CORRESP
1
filename1.htm
September
17, 2024
VIA
EDGAR
United
States Securities
and
Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Jane Park
Re:
bioAffinity
Technologies, Inc.
Registration
Statement on Form S-1
Filed
September 11, 2024
File
No: 333-282045
Dear
Ms. Park:
bioAffinity
Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration
Statement on Form S-1 (File No. 333-282045), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Thursday, September 19, 2024, at 4:00 p.m., Eastern Time, or as soon as reasonably practicable
thereafter.
The
Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware
of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration
Statement.
The
Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact
Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request
for acceleration has been granted.
Very truly yours,
BIOAFFINITY TECHNOGIES, INC.
By:
/s/ Maria Zannes
Name:
Maria Zannes
Title:
Chief Executive Officer
cc:
Leslie Marlow, Blank Rome LLP